Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Autor:	Jørgensen, S. F., Macpherson, M. E., Bjørnetrø, T., Holm, K., Kummen, M., Rashidi, A., Michelsen, A. E., Lekva, T., Halvorsen, B., Trøseid, M., Mollnes, T. E., Berge, R. K., Yndestad, A., Ueland, T., Karlsen, T. H., Aukrust, P., Hov, J. R., Fevang, B.
Předmět:	COMMON variable immunodeficiency GUT microbiome RANDOMIZED controlled trials RIFAXIMIN PROBIOTICS
Zdroj:	Scientific Reports; 2/15/2024, Vol. 14 Issue 1, p1-1, 1p
Abstrakt:	This document is a retraction note for an article titled "Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency" published in Scientific Reports. The authors have retracted the article because they discovered that 26% of the participants in the trial may have been using probiotics, which was an exclusion criterion. This discovery would lower the statistical power of the trial below 80%. All authors agree to the retraction. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.